Conditions: Alzheimer's Disease
Keywords: beta-secretase inhibitor
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 70
Healthy volunteers: no

Brief summary:
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque.

Detailed description:

Arms:
arm 1: LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks. arm 2: LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks. arm 3: LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks. arm 4: Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.

Interventions: intervention 1: LY2886721 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: